Inventor · disambiguated record
Huikai Sun
Also filed as: SUN HUIKAI
22 granted patents·5 pending applications·45 citations·filing 2013–2024
93Inventor score
Files withTAKEDA PHARMACEUTICALS CO18ENVOY THERAPEUTICS INC2TAKEDA PHARMACEUTICAL2BOUNDLESS BIO INC1BROWN JASON W1
Top patents by PatentIndex Score
27 records- 0188US9303045B25-HT3 receptor antagonistsTAKEDA PHARMACEUTICAL·Filed 2013·Granted Apr 5, 2016·7 cites·11 claims
- 0287US9012447B25-HT3 receptor antagonistsENVOY THERAPEUTICS INC·Filed 2013·Granted Apr 21, 2015·8 cites·15 claims
- 0386US12005054B2Piperidinyl-3-(aryloxy)propanamides and propanoatesTAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Jun 11, 2024·1 cites·19 claims
- 0486US11045457B2Piperidinyl-3-(aryloxy)propanamides and propanoatesTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Jun 29, 2021·5 cites·21 claims
- 0586US9346829B25-HT3 receptor antagonistsHITCHCOCK STEPHEN·Filed 2015·Granted May 24, 2016·5 cites·2 claims
- 0685US9670229B25-HT3 receptor antagonistsTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Jun 6, 2017·3 cites·11 claims
- 0784US9770452B2Quinoxaline derivatives as GPR6 modulatorsTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Sep 26, 2017·4 cites·22 claims
- 0880US9487526B2Quinoxaline derivatives as GPR6 modulatorsENVOY THERAPEUTICS INC·Filed 2013·Granted Nov 8, 2016·5 cites·21 claims
- 0977US10179783B2Tetrahydropyridopyrazines as modulators of GPR6TAKEDA PHARMACEUTICALS CO·Filed 2015·Granted Jan 15, 2019·2 cites·8 claims
- 1077US2025049772A1Piperidinyl-3-(aryloxy)propanamides and propanoatesTAKEDA PHARMACEUTICALS CO·Filed 2024·Application pending·0 cites
- 1175US10077266B2Substituted pyrido[3,4-b]pyrazines as GPR6 modulatorsTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Sep 18, 2018·1 cites·11 claims
- 1271US9708313B2Substituted pyrido[3,4-b]pyrazines as GPR6 modulatorsBROWN JASON W·Filed 2015·Granted Jul 18, 2017·1 cites·15 claims
- 1370US9181249B2Substituted pyrido[3,4-b]pyrazines as GPR6 modulatorsTAKEDA PHARMACEUTICAL·Filed 2014·Granted Nov 10, 2015·1 cites·19 claims
- 1469US10738046B2Substituted pyrido[3,4-b]pyrazines as GPR6 modulatorsTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Aug 11, 2020·0 cites·21 claims
- 1568US10597392B2Tetrahydropyridopyrazines as modulators of GPR6TAKEDA PHARMACEUTICAL CORPORATION LTD·Filed 2018·Granted Mar 24, 2020·1 cites·11 claims
- 1668US10407443B25-HT3 receptor antagonistsTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Sep 10, 2019·0 cites·14 claims
- 1768US10000468B2Pyrazines as modulators of GPR6TAKEDA PHARMACEUTICALS CO·Filed 2015·Granted Jun 19, 2018·1 cites·10 claims
- 1865US10125145B25-HT3 receptor antagonistsTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Nov 13, 2018·0 cites·12 claims
- 1964US2024228459A1Wee1 inhibitors and uses thereofBOUNDLESS BIO INC·Filed 2023·Application pending·0 cites
- 2063US2025340563A1Fused pyridazine derivatives as nlrp3 inhibitorsTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 2163US2018072758A15ht3 receptor antagonistsTAKEDA PHARMACEUTICALS CO·Filed 2017·Application pending·0 cites
- 2262US9695195B25-HT3 receptor antagonistsTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Jul 4, 2017·0 cites·9 claims
- 2361US10406157B2Tetrahydropyridopyrazine modulators of GPR6TAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Sep 10, 2019·0 cites·28 claims
- 2454US12428403B2N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonistsTAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Sep 30, 2025·0 cites·33 claims
- 2552US2023150981A1N-heteroarylalkyl-2-(heterocyclyl and heterocyclylmethyl) acetamide derivatives as sstr4 agonistsTAKEDA PHARMACEUTICAL COMPNAY LTD·Filed 2021·Application pending·0 cites
- 2651US10273225B2Pyrazines as modulators of GPR6TAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Apr 30, 2019·0 cites·12 claims
- 2743US11426397B2Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6TAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Aug 30, 2022·0 cites·17 claims
Join the waitlist — get patent alerts
Get an alert when Huikai Sun files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →